39 results on '"Beelen, Dietrich"'
Search Results
2. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Zeiser, Robert, Beelen, Dietrich W., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Burchert, Andreas, Christopeit, Maximilian, Duyster, Justus, Finke, Jürgen, Gerbitz, Armin, Klusmann, Jan Henning, Kobbe, Guido, Lübbert, Michael, Müller-Tidow, Carsten, Platzbecker, Uwe, Rösler, Wolf, Sauer, Martin, Schmid, Christoph, Schroeder, Thomas, and Stelljes, Mathias
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *CANCER stem cells , *MYELODYSPLASTIC syndromes , *CELL transplantation , *PROTEIN-tyrosine kinases - Abstract
Highlights • Major mechanisms of relapse include HLA loss, HLA down-regulation, and expression of coinhibitory ligands. • Combination of donor lymphocyte infusion with immunomodulating agents and tyrosine kinase inhibitors may enhance the graft-versus-leukemia (GVL) effect. • Immune checkpoint inhibitors can induce a significant GVL effect, but toxicity is high. ABSTRACT The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immunomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy, cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted therapies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, including occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently, prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Author
-
Ayuk, Francis, Beelen, Dietrich W., Bornhäuser, Martin, Stelljes, Matthias, Zabelina, Tatjana, Finke, Jürgen, Kobbe, Guido, Wolff, Daniel, Wagner, Eva-Maria, Christopeit, Maximilian, Schmid, Christoph, Ottinger, Hellmut, Groth, Christoph, Faul, Christoph, Bertz, Hartmut, Rachlis, Elena, Wolschke, Christine, Schetelig, Johannes, Horn, Peter A., and Mytilineos, Joannis
- Subjects
- *
HLA histocompatibility antigens , *ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *CYTOMEGALOVIRUSES , *HEMATOPOIETIC stem cell transplantation - Abstract
Highlights • The impact of donor age and sex but not CMV matching is comparable with that of single HLA disparity on survival after HSCT. • Similar survival after matched unrelated and related donor HSCT for AML or MDS reflects lower NRM but higher relapse risks in the latter. Abstract Increasing donor–recipient HLA disparity is associated with negative outcomes of allogeneic hematopoietic stem cell transplantation (HSCT), but its comparative relevance amid non-HLA donor characteristics is not well established. We addressed this question in 3215 HSCTs performed between 2005 and 2013 in Germany for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Donors were HLA-matched related (MRD; n = 872) or unrelated (10/10 MUD, n = 1553) or HLA-mismatched unrelated (<10/10 MMUD, n = 790). Overall survival (OS) was similar after MRD compared with 10/10 MUD HSCT, reflecting opposing hazards of relapse (hazard ratio [HR], 1.32; P <.002) and nonrelapse mortality (HR,.63; P <.001). After UD HSCT, increasing HLA disparity was associated with inferior OS (HR, 1.21 [ P <.02] and HR, 1.57 [ P <.001] for 9/10 and ≤8/10 MMUD, respectively, compared with 10/10 MUD). Among non-HLA donor characteristics, age, sex mismatching (male recipient–female donor), and cytomegalovirus (CMV) mismatching (positive recipient–negative donor) impacted OS. Multivariate subgroup analysis showed that OS was similar after HSCT from the youngest 9/10 MMUD (<30 years) compared with the oldest 10/10 MUD (>40 years) (HR, 1.18; P =.25) and also in male patients transplanted from female 10/10 MUD compared with male 9/10 MMUD (HR,.89; P =.46). In contrast, OS of CMV-positive patients tended to be better with CMV-negative 10/10 MUDs compared with CMV-positive 9/10 MMUDs (HR, 1.31; P =.04). Because of low patient numbers in subgroups, definite conclusions and establishment of a hierarchy among HLA matching and non-HLA donor characteristics could not be made. Our data suggest that the impact of donor age and sex mismatch but not CMV mismatch on outcome of allogeneic HSCT may be comparable with that of single HLA disparity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
- Author
-
Kasimir-Bauer, Sabine, Beelen, Dietrich, Flasshove, Michael, Noppeney, Richard, Seeber, Siegfried, and Scheulen, Max Ernst
- Subjects
- *
MYELOID leukemia , *GLYCOPROTEINS , *DIAGNOSIS - Abstract
: ObjectiveResistance to chemotherapy-induced apoptosis and a multidrug-resistance phenotype is the major problem in the treatment of acute myeloid leukemia (AML).: Patients and MethodsWe recently demonstrated that the coexpression of at least two proteins, including P glycoprotein, multidrug resistance-related protein, bcl-2 (flow cytometry), p53 (luminometric immunoassay), and heat shock protein 27 (Western blotting), was predictive for response to induction therapy in de novo AML comparing leukemic blasts of 20 responders with 20 nonresponders. After long-term follow-up, we now present our evaluation on the prognostic significance of these proteins in leukemic blasts of 124 untreated AML patients with regard to the probability of remission (PoR) and overall survival (OS).: ResultsAnalyzing leukemic blasts obtained from bone marrow samples, we found that no single protein significantly correlated with PoR or OS. In contrast, the coexpression of at least two of these proteins was predictive for reduced OS in univariate as well as multivariate analysis. Although we could not identify any particular protein combination predictive for reduced OS, those patients with no or only one protein expressed in their leukemic blasts had a survival probability of 48% in contrast to 24% in those patients with the coexpression of two or more proteins. Among the clinical markers, only response to chemotherapy had a significant effect on OS and age was of prognostic relevance for PoR.: ConclusionWe conclude that overexpression of only one protein possibly involved in resistance, is not sufficient to influence the prognosis for long-term survival in AML, whereas the expression of more than one protein is predictive for reduced OS. Protein combination seems to be individually different, and targeting only one protein in further clinical trials may not help to overcome multifactorial resistance. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
5. Megakaryopoiesis and Myelofibrosis in Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation: An Immunohistochemical Study of 127 Patients.
- Author
-
Thiele, Juergen, Kvasnicka, Hans Michael, Beelen, Dietrich Wilhelm, Flucke, Uta, Spoer, Christian, Paperno, Svetlana, Leder, Lutz-Dietrich, and Schaefer, Ulrich Wilhelm
- Published
- 2001
- Full Text
- View/download PDF
6. Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation.
- Author
-
Gran, Charlotte, Wang, Junfeng, Nahi, Hareth, Koster, linda, Gahrton, Gosta, Wolschke, Christine, Einsele, Hermann, Niittyvoupio, Riitta, Blaise, Didier, Niederwieser, Dietger, Meier, Ellen, Petersen, Eefke, de Wreede, Liesbeth C., Ljungman, Per, Bourhis, Jean Henri, Veelken, Hendrik, Beelen, Dietrich, Stelljes, Matthias, Gerbitz, Armin, and Vincent, Laure
- Published
- 2019
- Full Text
- View/download PDF
7. Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens
- Author
-
Beelen, Dietrich, Markiewicz, Miroslaw, Stelljes, Matthias, Remenyi, Peter, Wagner-Drouet, Eva-Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Michallet, Mauricette, Schaefer-Eckart, Kerstin, Grigoleit, Goetz, Scheid, Christof, Patriarca, Francesca, Mico, Maria Caterina, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, and Socié, Gerard
- Subjects
- *
CLINICAL trials , *BUSULFAN , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia - Abstract
Background Allogeneic hematopoietic stem cell transplantation (HCT) remains a challenge in elderly and comorbid AML and MDS patients. This patient population is at increased risk for non-relapse mortality (NRM) when treated with standard myeloablative conditioning and was selected to compare a newly developed treosulfan-based with a well-established reduced intensity busulfan-based preparative regimen in a prospective randomized clinical phase III trial. Methods Adult patients with AML in remission or MDS scheduled for HCT from matched related or unrelated donors, aged ≥50 years or with a comorbidity index (HCT-CI) of >2 were enrolled by a central stratified randomization procedure. Treatment arms consisted of intravenous (IV) treosulfan (10 g/m²/day [d-4 to d-2]) or IV busulfan (3.2 mg/kg/day [d-4 to d-3]), both combined with IV fludarabine (30 mg/m²/day [d-6 to d-2]). The primary objective was to compare event-free survival (EFS) at two years with relapse/progression of disease, graft failure, or death reported as events. Secondary endpoints were safety evaluation (according to CTCAE v4.03), engraftment, chimerism, overall survival (OS), relapse/progression incidence (RI), NRM and acute or chronic GvHD. After a previously conducted confirmatory interim analysis (based on 476 patients), which resulted in early termination of patient accrual due to significant non-inferiority of treosulfan treatment with improved EFS, NRM and OS (Beelen et al., ASH 2017), results of the final analysis of all 570 randomized patients including post surveillance data are provided here. Results Median age of the 551 patients (352 AML; 199 MDS) included in the full analysis set (268 treosulfan; 283 busulfan) was 60 years (range: 31, 70). Frequencies of early adverse events (d-6 to d+28) and incidences of acute and chronic GvHD were largely comparable between the two regimens, while extensive chronic GvHD was numerically in favor of treosulfan (19.7% vs. 26.7%; p=0.0750). Primary neutrophil recovery at day +28 was comparable, while the rate of complete donor-type chimerism (day +28) was higher after treosulfan (93.2% vs. 83.3%; p<0.0001). After a median follow-up of 29 months (range: 3.0, 54.3) the 2-year EFS was significantly higher in the treosulfan arm (65.7% vs. 51.2%; hazard ratio [HR] 0.64; p=0.0012) as was OS (72.7% vs. 60.2%; HR 0.64; p=0.0037) and NRM (12.0% vs. 20.4%; HR 0.63; p=0.0343). RI was comparable between both regimens (22.0% vs. 25.2%; HR 0.82; p=0.2631). Results were consistent within all pre-defined major prognostic subgroups of patients. Conclusions Final evaluation of this phase III trial substantiates the previous confirmatory analysis resulting in significantly improved survival after treosulfan-based conditioning. Due to the reduction of NRM a major clinical benefit of the new treosulfan conditioning regimen was demonstrated in the selected AML/MDS patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
- Author
-
van Gelder, Michel, Ziagkos, Dimitris, de Wreede, Liesbeth, van Biezen, Anja, Dreger, Peter, Gramatzki, Martin, Stelljes, Matthias, Andersen, Niels Smedegaard, Schaap, Nicolaas, Vitek, Antonin, Beelen, Dietrich, Lindström, Vesa, Finke, Jürgen, Passweg, Jacob, Eder, Matthias, Machaczka, Maciej, Delgado, Julio, Krüger, William, Raida, Luděk, and Socié, Gerard
- Published
- 2017
- Full Text
- View/download PDF
9. The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS: A Refinement of the T Cell Epitope Group Algorithm for Permissive Mismatches.
- Author
-
Crivello, Pietro, Beelen, Dietrich W., Heinold, Andreas, Riebschläger, Sabine, Heinemann, Falko, Rebmann, Vera, Lindemann, Monika, Ottinger, Hellmut D., Horn, Peter A., and Fleischhauer, Katharina
- Subjects
- *
HLA histocompatibility antigens , *DISEASE relapse , *ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *CLINICAL trials - Published
- 2016
- Full Text
- View/download PDF
10. Interferon alpha (IFN) treatment of bone marrow stroma inhibits haematopoesis
- Author
-
Kasper, Christoph, Lübking, Anna, Beelen, Dietrich W., and Dührsen, Ullrich
- Subjects
- *
HEMATOPOIETIC system , *IMMUNE system , *ANTIGEN presenting cells , *LEUCOCYTOSIS - Abstract
Prolonged pre-transplant IFN administration in patients with chronic myeloid leukaemia has been associated with an increased risk of fatal transplant-related complications and an inferior outcome after allogeneic bone marrow transplantation. Using a two-stage long-term bone marrow culture as an in vitro model we were able to show a negative effect of higher doses of IFN pre-treatment of bone marrow stroma on haematopoesis. This correlated with a decline in the number of monocytes–macrophages. While monocytes–macrophages itself produce cytokines, a vicious circle may lead to an ineffective function of the microenvironment resulting in ineffective haematopoieses and increased transplant-related complications. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
11. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
- Author
-
Carré, Martin, Porcher, Raphaël, Finke, Jürgen, Ehninger, Gerhard, Koster, Linda, Beelen, Dietrich, Ganser, Arnold, Volin, Liisa, Lozano, Sara, Friis, Lone, Michallet, Mauricette, Tischer, Johanna, Olavarria, Eduardo, Cascon, Maria Jesús Pascual, Iacobelli, Simona, Koc, Yener, Jindra, Pavel, Arat, Mutlu, de Witte, Theo, and Yakoub Agha, Ibrahim
- Subjects
- *
BLOOD groups , *HEMATOPOIETIC stem cell transplantation , *COMORBIDITY , *STEM cell transplantation , *ALEMTUZUMAB , *KARNOFSKY Performance Status , *BONE marrow - Abstract
• Allotransplant for myelodysplastic syndrome is limited by high nonrelapse mortality. • Comorbidities assessed by the original Sorror score impact mortality negatively. • Chronological age also continues to play an independent prognostic role on mortality. • Both age and comorbidities should be integrated in the allotransplant decision process. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P =.016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P =.022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P <.0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
- Author
-
McLornan, Donal, Szydlo, Richard, Koster, Linda, Chalandon, Yves, Robin, Marie, Wolschke, Christine, Beelen, Dietrich, Socié, Gerard, Bornhäuser, Martin, Angelucci, Emanuele, Niederwieser, Dietger, Gerbitz, Arnim, Finke, Jürgen, Vitek, Antonin, Itälä-Remes, Maija, Radujkovic, Aleksandar, Kanz, Lothar, Potter, Victoria, Chevallier, Patrice, and Stelljes, Matthias
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYCOSIS fungoides , *MYELOFIBROSIS , *NATALIZUMAB , *STEM cell transplantation , *KARNOFSKY Performance Status , *BONE marrow , *ALEMTUZUMAB - Abstract
• In this largest cohort of myelofibrosis transplants analyzed to date, no significant difference in 5-year probabilities of overall survival (OS) was noted between those undergoing myeloablative conditioning (MAC) (53.0%; 95% confidence interval [CI], 49.1% to 56.9%) and reduced-intensity conditioning (RIC) (51.0%; 95% CI, 48.3% to 53.7%); P =.78. • Graft failure rates appeared higher in those undergoing RIC protocols compared with MAC protocols. • MAC platforms demonstrated a trend toward less relapse and significantly improved graft-versus-host disease-free/relapse-free survival, although this requires validation. This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT) between 2000 and 2014; 781 (35%) underwent myeloablative conditioning (MAC) and 1443 (65%) reduced-intensity conditioning (RIC). Median patient age was 52.9 years (range, 18 to 74 years) and 57.5 years (range, 21 to 76 years) in the MAC and RIC cohorts, respectively. Donor type was similar: matched sibling donors (MAC, 317 [41%]; RIC, 552 [38%]) and unrelated donors (MAC, 464 [59%]; RIC, 891 [62%]). Median time to both neutrophil and platelet (>20 × 109/L) engraftment did not differ between cohorts. Rates of grade II to IV acute GVHD were 28% (MAC) and 31% (RIC; P = NS). Cumulative chronic GVHD rates (limited/extensive) were 22%/27% (MAC) and 19%/31% (RIC; P =.10). Cumulative incidences of nonrelapse mortality (NRM) at 1, 3, and 5 years were 25.5%, 32.2%, and 34.6% (MAC) and 26.3%, 32.8%, and 34.4% (RIC), respectively. There was a trend toward a higher relapse rate with RIC regimens compared with MAC (P =.08); rates at 1, 3, and 5 years were 10.9%, 17.2%, and 20.1% (MAC) and 14%, 19.7%, and 23.2% (RIC), respectively. No significant difference in 5-year probabilities of overall survival (OS) was noted: MAC (53.0%; 95% confidence interval [CI], 49.1% to 56.9%) and RIC (51.0%; 95% CI, 48.3% to 53.7%); P =.78. Regarding the composite end point of GVHD-free/relapse-free survival (GRFS), the unadjusted Kaplan-Meier estimate of 5-year GRFS was 32.4% (95% CI, 29.0% to 36.1%) in the MAC group and 26.1% (95% CI, 23.9% to 28.2%) in the RIC group (P =.001). In the MAC cohort, multivariable analysis confirmed worse OS and NRM with older age (>50 years), using an unrelated donor and a Karnofsky Performance Status of 80 or less. For the RIC cohort, worse OS and NRM were associated with age 60 to 70 years compared with younger recipients, use of a mismatched donor, and poor performance status. In conclusion, although similar OS rates existed for both cohorts overall, this study suggests that MAC should still be used for younger individuals suitable for such an approach due to a trend toward less relapse and an overall suggested advantage of improved GRFS, albeit this should be examined in a more homogeneous cohort. RIC allo-SCT still offers significant survival advantage in the older, fitter MF allograft patient, and optimization to reduce significant relapse and NRM rates is required. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Shimoni, Avichai, Labopin, Myriam, Savani, Bipin, Byrne, Michael, Volin, Liisa, Finke, Jürgen, Niederwieser, Dietger, Ehninger, Gerhard, Blaise, Didier, Beelen, Dietrich, Tabrizi, Reza, Sengeloev, Henrik, Ganser, Arnold, Cornelissen, Jan J., Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *ACUTE leukemia , *SIBLINGS , *BONE marrow , *ALEMTUZUMAB - Abstract
• Marked improvement has been achieved in recent years in stem cell transplantation (SCT) from unrelated donors. • Long-term outcome is equivalent after SCT from unrelated and sibling donors. • Patients who are leukemia-free 2 years after SCT can expect a favorable outcome. Allogeneic stem cell transplantation (SCT) is potentially curative therapy in acute myeloid leukemia (AML). Marked improvement has been achieved with SCT from matched unrelated donors (MUDs) in recent years. However, there are limited data comparing the long-term outcomes (beyond 10 years) after SCT from sibling donors and MUDs in older patients with AML. We analyzed these outcomes in a large cohort of patients with AML (n = 1134), age ≥50 years, who were alive and leukemia-free 2 years after SCT from matched siblings (n = 848) or MUDs (n = 286), with a median follow-up of 8.9 years. The median age was 56 and 58 years after SCT from siblings and MUDs, respectively (P =.005). In the sibling group, 77%, 12%, and 11% were in first complete remission (CR1), second complete remission (CR2), and active leukemia at SCT compared with 50%, 25%, and 25% in the MUD group, respectively (P <.001). Sixty-one percent of siblings and 62% of MUDs had reduced-intensity conditioning (P =.78). The 10-year leukemia-free survival (LFS) of patients surviving leukemia-free 2 years after SCT was 72% and 62%, respectively (P =.30). Multivariate analysis identified active leukemia at SCT (hazard ratio [HR], 1.86; P =.0001) or CR2 (HR, 1.51; P =.02) compared with CR1, female recipients (HR, 0.71; P =.006), adverse cytogenetics (HR, 2.52; P =.01), and prior graft-versus-host disease (HR, 1.31; P =.04) as independent factors predicting LFS. Donor and conditioning type were not significant. The cumulative incidence was 15% and 17% (P =.97) for late relapse mortality and 13% and 21% for late nonrelapse mortality, respectively (P =.15). In conclusion, long-term LFS is similar, and patients who are leukemia-free 2 years after SCT can expect favorable outcomes with both donor types. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Microbiologic Diagnostic Workup of Acute Respiratory Failure with Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation: Findings in the Era of Molecular- and Biomarker-Based Assays.
- Author
-
Wohlfarth, Philipp, Turki, Amin T., Steinmann, Joerg, Fiedler, Melanie, Steckel, Nina K., Beelen, Dietrich W., and Liebregts, Tobias
- Subjects
- *
ADULT respiratory distress syndrome , *HEMATOPOIETIC stem cell transplantation , *BIOLOGICAL tags , *RETROSPECTIVE studies , *PATIENTS , *PREVENTION - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) recipients frequently develop acute respiratory failure (ARF) with pulmonary infiltrates. Molecular- and biomarker-based assays enhance pathogen detection, but data on their yield in this population are scarce. This was a retrospective single-center study of 156 consecutive HSCT recipients admitted to the intensive care unit (ICU) between May 2013 and July 2017. Findings from a microbiologic diagnostic workup using currently available methods on bronchoalveolar lavage (BAL) and blood samples from 66 patients (age, 58 years [range, 45 to 64]; HSCT to ICU, 176 days [range, 85 to 407]) with ARF and pulmonary infiltrates were analyzed. In 47 patients (71%) a causative pathogen was identified (fungal, n = 28; viral, n = 26; bacterial, n = 18). Polymicrobial findings involving several pathogen groups occurred in 20 patients (30%). Culture (12/16, 75%), galactomannan (13/15, 87%), and Aspergillus -PCR (8/9, 89%) from BAL but not serum galactomannan (6/14, 43%) helped to diagnose invasive aspergillosis (n = 16, 24%). Aspergillus -PCR detected azole resistance in 2 cases. Mucorales was found in 7 patients (11%; BAL culture, n = 6; Mucorales-PCR, n = 1). Patients with identified pathogens had higher Simplified Acute Physiology Score II scores ( P = .049) and inferior ICU survival (6% versus 37%, P < .01), which largely related to the presence of an invasive fungal infection. Eight patients (12%) had 1 or more viruses with uncertain lung pathogenicity as the sole microbiologic finding. A diagnostic microbiologic workup incorporating molecular- and biomarker-based assays identified pathogens in most HSCT recipients with ARF and pulmonary infiltrates admitted to the ICU. Implications of polymicrobial infection and pathogen patterns in these patients warrant further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
- Author
-
Giebel, Sebastian, Labopin, Myriam, Potter, Michael, Poiré, Xavier, Sengeloev, Henrik, Socié, Gerard, Huynh, Anne, Afanasyev, Boris V., Schanz, Urs, Ringden, Olle, Kalhs, Peter, Beelen, Dietrich W., Campos, Antonio M., Masszi, Tamás, Canaani, Jonathan, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
LEUKEMIA , *SPONTANEOUS cancer regression , *HEMATOPOIETIC stem cell transplantation , *LYMPHOCYTIC leukemia , *MULTIVARIATE analysis , *STATISTICS , *SURVIVAL , *DISEASE relapse , *DISEASE incidence , *DISEASE remission , *RETROSPECTIVE studies , *ODDS ratio , *PROGNOSIS - Abstract
Background Allogeneic haematopoietic stem cell transplantation (alloHSCT) is considered a standard treatment for patients with Philadelphia chromosome–positive acute lymphoblastic leukaemia (Ph+ ALL) achieving complete remission after induction containing tyrosine kinase inhibitors (TKIs). Methods We retrospectively compared results of myeloablative alloHSCT from either matched sibling donor (MSD) or unrelated donor (URD) with autologous (auto) HSCT for adults with Ph+ ALL in molecular remission, treated between 2007 and 2014. Results In univariate analysis, the incidence of relapse at 2 years was 47% after autoHSCT, 28% after MSD-HSCT and 19% after URD-HSCT ( P = 0.0002). Respective rates of non-relapse mortality were 2%, 18%, and 22% ( P = 0.001). The probabilities of leukaemia-free survival were 52%, 55% and 60% ( P = 0.69), while overall survival rates were 70%, 70% and 69% ( P = 0.58), respectively. In multivariate analysis, there was a trend towards increased risk of overall mortality after MSD-HSCT (hazard ratio [HR], 1.5, P = 0.12) and URD-HSCT (HR, 1.6, P = 0.08) when referred to autoHSCT. The use of total body irradiation (TBI)–based regimens was associated with reduced risk of relapse (HR, 0.65, P = 0.02) and overall mortality (HR, 0.67, P = 0.01). Conclusion In the era of TKIs, outcomes of myeloablative autoHSCT and alloHSCT for patients with Ph+ ALL in first molecular remission are comparable. Therefore, autoHSCT appears to be an attractive treatment option potentially allowing for circumvention of alloHSCT sequelae. Irrespective of the type of donor, TBI-based regimens should be considered the preferable type of conditioning for Ph+ ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
- Author
-
Shimoni, Avichai, Labopin, Myriam, Savani, Bipin, Hamladji, Rose-Marie, Beelen, Dietrich, Mufti, Ghulam, Socié, Gerard, Delage, Jeremy, Blaise, Didier, Chevallier, Patrice, Forcade, Edouard, Deconinck, Eric, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *BUSULFAN , *FLUDARABINE , *BONE marrow - Abstract
Dose intensity of the conditioning regimen has significant impact on the outcomes after stem cell transplantation (SCT) for acute myeloid leukemia. Most studies have shown more relapse, less nonrelapse mortality (NRM), and similar overall survival after reduced-intensity and myeloablative conditioning. There are limited data on the dose equivalence and expected outcomes of treosulfan-based compared with busulfan-based conditioning. We compared SCT outcomes after fludarabine with either intravenous busulfan at a myeloablative dose (FB4, 12.8 mg/kg, n = 1265) or a reduced dose (FB2, 6.4 mg/kg, n = 1456) or treosulfan at 42 g/m 2 (FT14, n = 403) or 36 g/m 2 (FT12, n = 168). Median patient age was 48, 60, 57, and 60 years in the FB4, FB2, FT14, and FT12 groups, respectively ( P < .0001). Two-year overall survival was 58%, 53%, 53%, and 51%, respectively ( P = .25). Multivariate analysis identified advanced age, advanced disease status, and secondary leukemia to be associated with worse survival. Relapse rate was 30%, 35%, 34%, and 40%, respectively. Relapse was more common after FB2, advanced age and disease status, secondary leukemia, and sibling donors. NRM was 17%, 18%, 21%, and 16%, respectively. NRM was least common after FT12 and more common with advanced age and disease status and unrelated donors. Treosulfan-based regimens were associated with lower rates of graft-versus-host disease. There was no difference in any outcome among patients in first complete remission at transplantation. However, there was better survival with treosulfan-based conditioning in advanced leukemia. In conclusion, survival is determined mostly by disease biology and is similar after various regimens. Treosulfan-based conditioning is more similar to myeloablative than to reduced-intensity conditioning but can be administered safely in older patients, with lower rates of graft-versus-host disease and possibly better outcomes in patients with active leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
- Author
-
Garderet, Laurent, Ziagkos, Dimitris, van Biezen, Anja, Iacobelli, Simona, Finke, Jürgen, Maertens, Johan, Volin, Liisa, Ljungman, Per, Chevallier, Patrice, Passweg, Jakob, Schaap, Nicolaas, Beelen, Dietrich, Nagler, Arnon, Blaise, Didier, Poiré, Xavier, Yakoub-Agha, Ibrahim, Lenhoff, Stig, Craddock, Charles, Schots, Rik, and Rambaldi, Alessandro
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELODYSPLASTIC syndromes treatment , *HOMOGRAFTS , *DELETION mutation , *DISEASE incidence , *SURVIVAL analysis (Biometry) - Abstract
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
- Author
-
Ahci, Müberra, Stempelmann, Karin, Buttkereit, Ulrike, Crivello, Pietro, Trilling, Mirko, Heinold, Andreas, Steckel, Nina Kristin, Koldehoff, Michael, Horn, Peter A., Beelen, Dietrich W., and Fleischhauer, Katharina
- Subjects
- *
STEM cell transplantation , *CHIMERISM , *BONE marrow , *CYTOMEGALOVIRUSES , *IMMUNOSUPPRESSIVE agents - Abstract
Although quantitative PCR (qPCR) has been explored for chimerism monitoring after allogeneic stem cell transplantation (SCT), evidence regarding its clinical utility compared with standard short tandem repeat (STR) is still limited. We retrospectively studied commercial qPCR and STR chimerism with respective positivity thresholds of .1% and 1% in 359 peripheral blood (PB) and 95 bone marrow (BM) samples from 30 adult patients after first HLA-matched SCT for myeloid malignancies or acute lymphatic leukemia. Concordance between the 2 methods was 79.5%, with all discordant samples positive in qPCR but negative in STR. Of the latter, sporadic qPCR positivity without clinical correlates was seen mostly in BM samples early post-transplant. In 7 of 21 patients with available follow-up samples in the first months after transplantation, qPCR but not STR revealed low levels (<1%) of sustained host chimerism in PB, reflecting delayed engraftment or persistent mixed chimerism (PMC). These conditions were associated with donor–recipient cytomegalovirus (CMV) serostatus and early CMV reactivation but not with immunosuppressive regimens or clinical outcome. qPCR predicted all 8/8 relapses with samples in the 6 months before onset by sustained positivity in both PB and BM compared with 1/8 relapses predicted by STR mainly in BM. The response kinetics to donor lymphocyte infusions for the treatment of PMC or relapse was shown by qPCR but not STR to be protracted over several months in 3 patients. Our results demonstrate the superior clinical utility of qPCR compared with STR for monitoring subtle changes of host chimerism associated with different clinical conditions, making a case for its use in the clinical follow-up of transplant patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
- Author
-
Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Jürgen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yáñez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, and Stelljes, Matthias
- Subjects
- *
STEM cell transplantation , *MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia , *KARNOFSKY Performance Status , *RETROSPECTIVE studies - Abstract
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% ( P = .01) and 46% ( P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation.
- Author
-
Merz, Maximilian, Jansen, Lina, Castro, Felipe A., Hillengass, Jens, Salwender, Hans, Weisel, Katja, Scheid, Christof, Luttmann, Sabine, Emrich, Katharina, Holleczek, Bernd, Katalinic, Alexander, Nennecke, Alice, Straka, Christian, Langer, Christian, Engelhardt, Monika, Einsele, Hermann, Kröger, Nicolaus, Beelen, Dietrich, Dreger, Peter, and Brenner, Hermann
- Subjects
- *
MULTIPLE myeloma treatment , *AUTOGRAFTS , *HEMATOPOIETIC stem cell transplantation , *SURVIVAL , *OLD age - Abstract
Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60–79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998–2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000–2002 and 2009–2011 (60–64years: 7.0–43.0%; 65–69 years: 6.6–23.7%; 70–79 years: 0.4–4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60–64: 59.2% versus 66.1%; 65–69: 57.4% versus 61.7%; 70–79: 51.0% versus 56.6%). RS increased strongly between 2003–2005 and 2009–2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003–2005 to 5.2% higher survival in 2009–2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Kharfan-Dabaja, Mohamed A., Labopin, Myriam, Bazarbachi, Ali, Socie, Gerard, Kroeger, Nicolaus, Blaise, Didier, Veelken, Hendrik, Bermudez, Arancha, Or, Reuven, Lioure, Bruno, Beelen, Dietrich, Fegueux, Nathalie, Hamladji, Rose Marie, Nagler, Arnon, and Mohty, Mohamad
- Subjects
- *
BUSULFAN , *DRUG dosage , *ACUTE leukemia , *HOMOGRAFTS , *BONE marrow transplantation , *PATIENTS , *LEUKEMIA treatment - Abstract
Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4 mg/kg ± 10%) and FB4 (IV fludarabine plus IV busulfan 12.8 mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 ( n = 88) or FB4 ( n = 40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5–38) days) or FB4 (16 (9–29) days), p = 0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR = 0.44 (95%CI = 0.21, 0.94), p = 0.03) and overall survival (HR = 0.38 (95%CI = 0.16, 0.86), p = 0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI = 14–28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Maternal molecular features and gene profiling of monocytes during first trimester pregnancy.
- Author
-
Koldehoff, Michael, Cierna, Barbara, Steckel, Nina K., Beelen, Dietrich W., and Elmaagacli, Ahmet H.
- Subjects
- *
GENE expression profiling , *MONOCYTES , *FIRST trimester of pregnancy , *MOLECULAR biology , *PREGNANT women , *IMMUNOREGULATION , *MATERNAL health services , *OLIGONUCLEOTIDE arrays - Abstract
Abstract: We examined the molecular characteristics of monocytes of pregnant and non-pregnant women to investigate the molecular effects that are associated with immunoregulation at the maternal–fetal interface. We analyzed molecular features and target genes in monocytes of pregnant women using flow cytometry, real-time PCR and oligonucleotide microarray technology. CD14high monocytes and several immune gene members including CD200, CD200R, IDO, IFI27, IL-10 and G0S2 were found to be differentially expressed in monocytes throughout pregnancy. In addition, transcripts within components of the signaling cascade of immune cells (HLA-DRB4, HBEGF, IL-8, CD3D, CCL5), and of several transcription factors (SOCS1, CXCL10, ID1, ID2) were altered in the monocytes of pregnant women. Further studies will be needed to elucidate the biological significance of our observation. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
23. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
- Author
-
Platzbecker, Uwe, Schetelig, Johannes, Finke, Jürgen, Trenschel, Rudolf, Scott, Bart L., Kobbe, Guido, Schaefer-Eckart, Kerstin, Bornhäuser, Martin, Itzykson, Raphael, Germing, Ulrich, Beelen, Dietrich, Ehninger, Gerhard, Fenaux, Pierre, Deeg, H. Joachim, and Adès, Lionel
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia , *BLOOD donors , *AZACITIDINE , *COMPARATIVE studies , *DISEASE risk factors - Abstract
Standard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS) includes hypomethylating agents, such as azacitidine (AZA). However, the only approach with curative potential remains allogeneic hematopoietic cell transplantation (HCT). To date, no direct comparison of both strategies has been reported. The outcomes of 2 well-balanced cohorts of patients with high-risk MDS defined by age (60-70 years), performance status (Eastern Cooperative Oncology Group score ≤2), and donor availability (yes/no) were compared, including 103 patients undergoing HCT and 75 patients without this option who received AZA. The estimated 2-year overall survival after the start of treatment was 39% (95% confidence interval, 30%-50%) for the patients undergoing HCT and 23% (95% confidence interval, 14%-40%) for the patients receiving AZA therapy. In a multivariate Cox regression analysis of all patients (n = 178), Eastern Cooperative Oncology Group score (0 versus 1 versus 2; hazard ratio [HR], 2.9/3.9; P < .001), cytogenetics (good versus intermediate versus poor; HR, 1.2/1.7; P = .026), and treatment (HCT versus AZA; HR, 0.3; P = .007) were associated with overall survival. This retrospective cohort analysis suggests a survival advantage for allogeneic HCT compared with AZA therapy in medically fit patients with high-risk MDS age 60-70 years. Prospective controlled studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Comparison of Cytogenetic Clonal Evolution Patterns following Allogeneic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of AML
- Author
-
Bacher, Ulrike, Haferlach, Torsten, Alpermann, Tamara, Zenger, Melanie, Kröger, Nicolaus, Beelen, Dietrich W., Kern, Wolfgang, Schnittger, Susanne, and Haferlach, Claudia
- Subjects
- *
COMPARATIVE studies , *CYTOGENETICS , *BIOLOGICAL evolution , *HEMATOPOIETIC stem cell transplantation , *DISEASE relapse , *ACUTE myeloid leukemia , *ACUTE leukemia , *PATIENTS , *LEUKEMIA treatment - Abstract
Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT). We compared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n = 26) or standard chemotherapy (n = 134) using chromosome banding analysis combined with fluorescein in situ hybridization. There were 71 females and 89 males (19.7-80.6 years). At diagnosis, aberrant karyotypes were more frequent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%). This was most obvious in patients with unfavorable cytogenetics (8 of 26; 30.8% versus 19 of 134; 14.2%; P = .032). Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort (14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.), mainly because of newly emerging cytogenetic alterations. Appearance of ≥3 new clonal alterations was more frequent in the allo-cohort (6 of 12; 50.0% with clonal evolution versus 5 of 41; 12.2%, P = .005). The mean number of cytogenetic alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the conventionally treated patients from 0.9 to 1.3 (both P < .001). Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
25. Allogeneic Stem Cell Transplantation for AML Patients with RUNX1 Mutation in First Complete Remission: A Study on Behalf of the ALWP of the EBMT.
- Author
-
Waidhauser, Johanna, Labopin, Myriam, Esteve, Jordi, Kröger, Nicolaus, Cornelissen, Jan, Gedde-Dahl, Tobias, Van Gorkom, Gwendolyn, Finke, Jürgen, Rovira, Montserrat, Schaap, Nicolaas, Petersen, Eefke, Beelen, Dietrich Wilhelm, Bunjes, Donald W., Schmid, Christoph, Nagler, Arnon, and Mohty, Mohamad
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *ACUTE leukemia , *KARYOTYPES , *MULTIVARIATE analysis , *UNIVARIATE analysis - Abstract
Acute myeloid leukemia bearing a RUNX1 gene mutation (RUNX1 + AML) has been proposed as a provisional entity in the 2016 WHO classification. Clinically, it has been associated with inferior response rates and outcome after conventional chemotherapy. Accordingly, RUNX1 + AML is allocated in the unfavorable prognostic category of the 2017 European Leukemia Net classification. Following allogeneic stem cell transplantation (alloSCT), RUNX1 was an unfavorable factor in one study in MDS/secondary AML, while data in de novo AML are scarce. Here, we present a retrospective study by the EBMT Acute Leukemia Working Party, aiming to elucidate the prognostic value of RUNX1 mutation in patients undergoing alloSCT for AML in first complete remission (CR1). Adults undergoing alloSCT for AML in CR1 from matched related or unrelated donors between 2013 and 2018 with complete information on conventional cytogenetics and RUNX1 mutational status were selected from the EBMT registry. Variables of interest were overall and leukemia-free survival (OS/LFS), GvHD/relapse free survival (GRFS), cumulative relapse incidence (RI), non-relapse mortality (NRM) and GvHD. Log rank test, Gray test and Cox regression models were used. 128 RUNX+ and 388 RUNX- patients were identified, >80% of both subgroups presenting as de novo AML. As expected, RUNX1+ patients rarely had co-mutations in NPM1 (6% vs. 26%, p=10−3), and showed a positive correlation with ASXL1 mutations (50% vs. 16%, p=10−4). Cytogenetic categories and other mutations (FLT3 -ITD, CEBPA) were equally distributed between the two groups, as were age, donor and graft type, CMV, conditioning and T cell depletion (TCD). Median follow-up was 16.4 (RUNX+) and 19.8 (RUNX-) months. 2y OS/LFS of the entire cohort were 64% [59-69]/57% [52-62], with no difference between RUNX1 + and RUNX1 - patients either in univariate or multivariate analysis (2y OS: 67.9% [57.3-78.5] vs. 63.1%v[57.4-68.7]p=0.15; 2y LFS: 57.6% [46.4-68.7] vs. 57% [51.4-62.6], p=0.38], figure 1). RUNX1 mutation neither had any impact among patients with normal karyotype (figure 2). Similarly, no other outcome parameter was influenced by RUNX1 mutational status. Instead, multivariate analysis revealed age and donor type as risk factors for OS, LFS and NRM. Poor cytogenetic was associated with higher RI and inferior LFS/GRFS, in vivo TCD with a lower rate of aGvHD II-IV, cGvHD, and better GRFS. Among patients with available information, FLT3 -ITD was an independent risk factor for relapse, LFS and GRFS. RUNX1 did not modify the role of FLT3 -ITD. Within the limits of a retrospective registry analysis, we could not find a negative influence of RUNX1 mutation on outcome after allogeneic SCT in CR1. Hence, transplantation in CR1 might overcome the unfavorable prognostic value of RUNX1 mutation and can be recommended as consolidation treatment in this entity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients
- Author
-
Lindemann, Monika, Ottinger, Hellmut D., Elmaagacli, Ahmet H., Trenschel, Rudolf, Rebmann, Vera, Beelen, Dietrich W., and Grosse-Wilde, Hans
- Subjects
- *
HEMATOPOIETIC stem cells , *BONE marrow cells , *IMMUNOGLOBULINS , *MOLECULAR cloning - Abstract
Objective: In the hematopoietic stem cell transplantation setting, granulocyte colony-stimulating factor (G-CSF) administration can reduce donor cell reactivity in vitro, but the clinical significance of this phenomenon was only sparsely defined. Methods: We performed lymphocyte transformation tests in 28 related stem cell donors pre and 5 days post G-CSF treatment, respectively, and correlated proliferative responses of donor peripheral blood mononuclear cells with clinical parameters in the corresponding recipients. Results: In vitro reactions towards 4 mitogens and 12 recall antigens at day 5 post G-CSF administration were predictive for the occurrence of chronic graft-vs-host disease (cGVHD). Here, proliferative responses towards the mitogen anti-CD3 monoclonal antibody (OKT3) above median were most informative; this threshold could be determined by discrimination and receiver operating curve (ROC) analyses. In the whole cohort (18 human leukocyte antigen [HLA]-identical and 10 partially mismatched donor-recipient pairs), OKT3 responses predicted cGVHD with an odds ratio of 33.0, a sensitivity of 79%, and a specificity of 90%. A subgroup analysis of HLA-identical pairs even yielded an odds ratio of 85.0. Furthermore, bivariate analysis defined HLA compatibility and responses towards OKT3 as independent risk factors for cGVHD (p = 0.02 and p = 0.0007, respectively). Conclusion: The proliferative capacity of G-CSF-mobilized donor cells appears as a graft factor that determines the future incidence of cGVHD in the corresponding recipient. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
27. Influence of telomere length on short-term recovery after allogeneic stem cell transplantation
- Author
-
Widmann, Thomas Alexander, Willmann, Barbara, Pfreundschuh, Michael, and Beelen, Dietrich W.
- Subjects
- *
STEM cells , *TELOMERES , *CELLULAR therapy , *HEMATOPOIETIC stem cells - Abstract
Objective: Telomeres shorten in somatic cells during aging and states of increased turnover, including hematopoietic stem cell transplantation. Fast hematopoietic recovery is critical for the patients'' course after hematopoietic stem cell transplantation. It is unknown whether telomere length in hematopoietic stem cells (HSCs) predicts short-term hematopoietic recovery. Methods: We quantified telomere length by flow fluorescence in situ hybridization analysis in HSCs and granulocytes of healthy stem cell donors and monitored time to peripheral blood cell recovery in transplanted hosts. Furthermore, we measured in vitro repopulation potency of HSCs by assaying for colony-forming units granulocyte-macrophage (CFU-GM). Results: Telomere length in HSC shortens continuously in vivo and is comparable to telomere length in granulocytes from the same individual. Numbers of in vitro formed CFU-GM per HSC show an inverse relationship to age and telomere length. However, telomere length in HSCs was not correlated with short-term recovery after HSC transplantation. Conclusion: These findings suggest that healthy stem cell donors have sufficient telomere length reserve to repopulate a myeloablatively treated host, despite continuous aging of HSCs in vivo and decreased repopulation ability of HSCs from older donors in vitro. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
28. Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation
- Author
-
Liedtke, Wolfgang, Quabeck, Klaus, Beelen, Dietrich W., Straeten, Vera, and Schaefer, Ulrich W.
- Published
- 1994
- Full Text
- View/download PDF
29. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
- Author
-
Alchalby, Haefaa, Zabelina, Tatjana, Stübig, Thomas, van Biezen, Anja, Bornhäuser, Martin, Di Bartolomeo, Paolo, Beelen, Dietrich, Cahn, Jean Yves, Dreger, Peter, Schroyens, William, de Witte, Theo, Olavarria, Eduardo, and Kröger, Nicolaus
- Subjects
- *
STEM cell transplantation , *MYELOFIBROSIS , *ACUTE myeloid leukemia , *MORTALITY , *MYELOPROLIFERATIVE neoplasms , *BONE marrow transplantation , *CONFIDENCE intervals , *THERAPEUTICS - Abstract
Abstract: Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
30. Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
- Author
-
Gagelmann, Nico, Ditschkowski, Markus, Bogdanov, Rashit, Cassinat, Bruno, Robin, Marie, Heuser, Michael, Thol, Felicitas, Shahswar, Rabia, Beelen, Dietrich, Badbaran, Anita, and Kröger, Nicolaus
- Subjects
- *
MYELOFIBROSIS , *STEM cell transplantation , *SURVIVAL analysis (Biometry) , *GENETIC mutation , *MULTIVARIATE analysis - Abstract
Background The Dynamic International Prognostic Scoring System (DIPSS) is commonly applied to predict survival among patients with primary myelofibrosis (PMF) but has been shown to perform less precisely in secondary myelofibrosis (SMF) and after transplantation. Furthermore, the prognostic relevance of mutation profile resulted in the mutation-enhanced IPSS (MIPSS70) in PMF, as well as in a model specific to SMF (MYSEC-PM). We aimed to develop a comprehensive clinical-molecular prognostic scoring system to determine outcome for myelofibrosis undergoing allogeneic stem cell transplantation. Patients and Methods We examined 361 myelofibrosis patients, of whom 260 had PMF and 101 SMF at time of transplantation. A training cohort of 205 patients was used to create a clinical-molecular transplant scoring system (MTSS) predicting survival from Cox models, internally validated by use of bootstrap and cross-validation. Model discrimination was measured by the concordance index (C). The final MTSS was externally validated in a cohort of 156 patients and was furthermore applied to posttransplant non-relapse mortality as a secondary objective. Results Multivariable analysis on 5-year survival identified age ≥57 years, Karnofsky performance status <90%, platelet count <150 × 109/L and leukocyte count >25 × 109/L at time of transplantation, HLA-mismatched unrelated donor, ASXL1 mutated and CALR -/ MPL -unmutated genotype being independent prognostic factors for outcome. The uncorrected concordance index for the final survival model was 0.723 (95% CI, 0.713-0.733), and bias-corrected indices were similar. A weighted score of 2 was assigned to transplantation from an HLA-mismatched unrelated donor and an CALR -/ MPL -unmutated genotype, whereas a score of 1 was assigned to older age, leukocytosis, thrombocytopenia, ASXL1 mutation, and poor performance status. The MTSS consisted of four distinct risk groups showing 5-year survival in the validation cohort of 83% (95% CI, 71-95%) for low (score 0-2), 64% (95% CI, 53-75%) for intermediate (score 3-4), 37% (95% CI, 17-57%) for high (score 5), and 22% (95% CI, 4-39%) for very high risk (score >5), respectively (P<0.001). Increasing score was predictive of non-relapse mortality (P<0.001) and remained applicable to PMF (C=0.718) and SMF (C=0.701) improving prognostic ability in comparison to current systems such as DIPSS (C=0.573), DIPSS-plus (C=0.557), MIPSS70 (C=0.587), MIPSS70-plus (C=0.547), as well as MYSEC-PM (C=0.605). Conclusion The MTSS integrates clinical, molecular as well as transplant-specific risk factors that independently affected survival. We show here that this internally and externally validated system accurately discriminated different risk for death and may improve counseling compared with currently existing systems, as well as facilitate design of clinical trials in the transplant setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT.
- Author
-
Shimoni, Avichai, Robin, Marie, Iacobelli, Simona, van Biezen, Anja, Beelen, Dietrich Wilhelm, Mufti, Ghulam J., Ciceri, Fabio, Kanz, Lothar, Volin, Liisa, Blaise, Didier, Ganser, Arnold, Luft, Thomas, Chevallier, Patrice, Schwerdtfeger, Rainer, de Witte, Theo, Kroger, Nicolaus, Nagler, Arnon, and Yakoub-Agha, Ibrahim
- Subjects
- *
STEM cell transplantation , *MYELODYSPLASTIC syndromes , *ALEMTUZUMAB , *CYTOGENETICS , *MULTIVARIATE analysis - Abstract
Allogeneic stem cell transplantation (SCT) is potentially curative therapy for patients with MDS. Prior studies have shown no overall-survival (OS) advantage of any conditioning regimen over the others. Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM) compared to myeloablative conditioning (MAC), however, relapse rates are higher, resulting in similar OS. Fludarabine and treosulfan (FT) is a reduced-toxicity regimen with intense anti leukemia activity in patients with myeloid malignancies. We explored outcomes following FT conditioning in comparison with other regimens. We retrospectively analyzed SCT outcomes of MDS patients reported to the chronic malignancies working party of EBMT (n=1722). The conditioning regimens were defined according to standard EBMT criteria and included FT (n=367), RIC (n=687) or MAC (n=668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0.001). More FT recipients had untreated MDS at SCT, 45%, 26% and 36%, respectively (P < 0.001). Disease status at diagnosis, cytogenetics, secondary origin and prior transformation to AML, were not different between the regimens. With a median follow-up of 20 months (1-171), 807 patients are alive, 328 died of relapse and 587 had NRM. The 5-year rates of relapse, NRM and OS for the entire group were 21% (95%CI, 19-23), 35% (95%CI, 33-38) and 44% (95%CI, 42-437), respectively. Relapse rates were similar after FT and MAC, 16% (13-21) and 19% (16-22), respectively, significantly lower than after RIC, 25% (21-28) (P = 0.003). Multivariate analysis (MVA) identified age >55 years (HR 1.42), advanced histology (RAEB 1/2, HR 2.01/ 1.73), prior transformation to AML (HR 1.87), refractory disease to prior therapies (HR 1.75) secondary origin (HR 1.33) and poor cytogenetics (HR 2.83) as associated with higher relapse risk. FT conditioning was associated with a lower risk (HR 0.63, P = 0.006). NRM was lower after FT and RIC than after MAC, 34% (29-39), 33% (30-37) and 38% (35-40), respectively (P = 0.05). MVA identified age >55 years (HR 1.39) and MAC (HR 1.34) as associated with higher NRM, while SCT from sibling donor (HR 0.81) and in CR (HR 0.80) were associated with a lower risk. In all, 5-year OS was 50% (44-55), 43% (38-47), and 43% (39-47), after FT, RIC and MAC, respectively (Figure 1, P = 0.03). MVA identified age >55 years (HR 1.39), advanced histology (RAEB 1/2, HR 1.35/ 1.10), prior transformation to AML (HR 1.37), and poor cytogenetics (HR 1.58) as associated with lower OS. FT conditioning was associated with better OS (HR 0.79, P = 0.01). FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved outcome over both RIC and MAC. FT might be the preferred regimen for SCT in MDS. These observations merit further study in randomized prospective trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party.
- Author
-
Schmid, Christoph, Labopin, Myriam, Socié, Gerard, Itälä-Remes, Maija, Blaise, Didier, Yakoub-Agha, Ibrahim, Milpied, Noel, Cornelissen, Jan, Ganser, Arnold, Beelen, Dietrich, Labussière-Wallet, Hélène, Passweg, Jakob, Savani, Bipin, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia treatment , *LEUKEMIA risk factors , *CANCER relapse , *CANCER remission - Abstract
Background Acute myeloid leukemia (AML) secondary to another haematological neoplasia or malignant disease (sAML) is thought to have an inferior prognosis than de novo AML. However, the role of this difference for allogeneic stem cell transplantation (SCT) is unclear. A registry-based analysis was performed to compare results after SCT for sAML versus AML. Methods Inclusion criteria were age ≥18y and SCT for de novo or sAML from a matched related, unrelated or T-cell replete haploidentical donor between 2000 and 2016. A multivariate Cox model was performed for risk factors for outcome. It was stratified for different stages at SCT. Further, a matched pair analysis of de novo versus sAML was done, using age (+/-3 years), stage at SCT, Karnofsky performance score (KPS), conditioning, in vivo/ex vivo T cell depletion, donor, donor/recipient sex and CMV-status combination, cytogenetics, and graft source as matching criteria. Results 11439 patients (pts) with de novo and 1325 with sAML were identified. Median follow-up was 36 and 33 months. After SCT in first complete remission (CR1), 3Y cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were 28.5%/16.4% for de novo (n=7691), and 35%/23.4% for sAML (n=909). 3Y overall survival (OS), leukemia-free survival (LFS) and GvHD/relapse free survival (GRFS) were 60.8%, 55.1% and 38.6% for de novo and 46.7%, 41.6% and 28.4% for sAML. In a multivariate Cox model focusing on SCT in CR1, sAML was associated with higher NRM (HR=1.32; p<10−5) and CIR (HR=1.28; p=0.0002), and lower LFS (HR=1.30; p<10−5), OS (HR=1.32; p<10−5) and GRFS (HR=1.20; p<10−5). Other factors for OS were age (p=<10-5), cytogenetics (intermediate, p=0.002, poor, p=<10-5), patient/donor sex combination (female/male, p=<10-5), KPS (<>80, p=0.003) and donor (UD 10/10 match, p=0.007; UD 9/10 match, p=10-5; haplo, p=0.002). When focusing on pts transplanted for primary refractory (de novo, n=607, sAML, n=199) or relapsed AML (de novo, n=1009, sAML, n=124), results were generally inferior. However, Cox models did not identify sAML as a relevant factor. Instead, outcome was determined by age, cytogenetics and KPS. The matched pair analysis was performed on 877 pairs and confirmed the above findings: Over all, sAML was associated with higher NRM (p=0.004), and lower LFS (p=0.004), OS (p=0.008) and GRFS (p=0.04). However, when the analysis was stratified by stage at SCT, again differences were only seen among pts transplanted in CR1, but not after SCT in advanced disease. Conclusion Our large-scale, registry-based analysis identified sAML as independent risk factor for outcome after SCT in first CR1. In primary refractory and relapsed AML, other factors such as age, cytogenetics and performance status were of higher relevance. This data may help to improve risk stratification and prognostic estimates after SCT for sAML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. The Role of Measurable Residual Disease (MRD) at Time of Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia Transplanted after Myeloablative Conditioning. A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Pavlu, Jiri, Labopin, Myriam, Niittyvuopio, Riitta, Socié, Gerard, Yakoub-Agha, Ibrahim, Wu, Depei, Remenyi, Peter, Passweg, Jakob, Beelen, Dietrich, Aljurf, Mahmoud, Kröger, Nicolaus, Labussière-Wallet, Hélène, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia treatment , *CANCER chemotherapy , *CANCER relapse , *CANCER remission - Abstract
Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning. Therefore, in this retrospective multicenter study we explored if MRD detectable before allogeneic HCT for ALL is associated with different outcomes in recipients of myeloablative TBI-based versus chemotherapy-based conditioning. We analyzed outcomes of 2780 patients (median age 38 years, range 18-72) who underwent first HCT in complete remission between 2000 and 2017 using sibling or unrelated 9/10 or 10/10 matched donors. In 1816 of these patients no disease was detectable before transplantation and in 964 patients MRD was detectable (MRD positivity). Conditioning was TBI-based in 2122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios (HR, 95% confidence intervals) of 1.19 (1.02-1.39), 1.26 (1.1-1.44), 1.51 (1.26-1.8). TBI was associated with a better OS, LFS and RI with HR of 0.75 (0.62-0.90), 0.70 (0.60-0.82) and 0.60 (0.49-0.74), respectively. No significant interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the TBI and chemotherapy-based conditioning cohorts by multivariate analysis, we found MRD positivity to be associated with lower OS (HR 1.26, 1.05-1.51) and LFS (HR 1.3,1.1-1.53), and higher RI (HR 1.53, 1.23-1.9) in the TBI group, and with higher RI (HR 1.58, 1.13-2.21) in the chemotherapy group. There was no significant association between MRD and other outcomes in this last cohort. TBI based conditioning was associated with improved OS, LFS, and RI in both MRD negative and MRD positive patients (figure). In this large study we confirmed that patients who are MRD negative prior to HCT achieve superior outcomes. This is particularly apparent if TBI conditioning is used. All patients with ALL irrespective of MRD status benefit from TBI based conditioning in myeloablative setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. 317 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT.
- Author
-
Ringden, Olle, Boumendil, Ariane, Labopin, Myriam, Canaani, Jonathan, Sadeghi, Behnam, Beelen, Dietrich W., Ehninger, Gerhard, Niederwieser, Dietger, Finke, Jürgen, Stelljes, Matthias, Arnold, Renate, Ganser, Arnold, Kroger, Nicolaus, Kanz, Lothar, Brecht, Arne, Savani, Bipin N., Mohty, Mohamad, and Nagler, Arnon
- Published
- 2018
- Full Text
- View/download PDF
35. 452 - What Is the Outcome of Patients with Acute Leukemia Who Survive Severe Acute Graft-Versus-Host Disease?
- Author
-
Ringden, Olle, Labopin, Myriam, Mailhol, Audry, Beelen, Dietrich W., Sadeghi, Behnam, Floisand, Yngvar, Ghavamzadeh, Ardeshir, Finke, Jürgen, Ehninger, Gerhard, Volin, Liisa, Ganser, Arnold, Schmid, Christoph, Giebel, Sebastian, and Nagler, Arnon
- Subjects
- *
ACUTE leukemia , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *PROGRESSION-free survival , *HEMATOLOGY , *PATIENTS - Published
- 2017
- Full Text
- View/download PDF
36. 18 - Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center.
- Author
-
Ciurea, Stefan O., Labopin, Myriam, Polge, Emmanuelle, Kongtim, Piyanuch, Rondon, Gabriela, Socié, Gerard, Volin, Liisa, Passweg, Jakob, Chevallier, Patrice, Beelen, Dietrich W., Milpied, Noel, Blaise, Didier, Cornelissen, Jan, Fegueux, Nathalie, Mohty, Mohamad, Savani, Bipin N., Champlin, Richard E., and Nagler, Arnon
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *KARYOTYPES , *MEDICAL centers , *BONE marrow transplantation - Published
- 2017
- Full Text
- View/download PDF
37. Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT.
- Author
-
Savani, Bipin N., Labopin, Myriam, Boumendil, Ariane, Ehninger, Gerhard, Ganser, Arnold, Ayuk, Francis, Stelljes, Matthias, Finke, Jürgen, Beelen, Dietrich, Niederwieser, Dietger, Stuhler, Gernot, Glass, Bertram, Arnold, Renate, Polge, Emmanuelle, Gorin, Norbert, Esteve, Jordi, Ciceri, Fabio, Baron, Frédéric, Schmid, Christoph, and Giebel, Sebastian
- Subjects
- *
HOMOGRAFTS , *HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *CLINICAL trials , *MEDICAL care - Published
- 2016
- Full Text
- View/download PDF
38. No Influence of V617F Mutation in JAK2 on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelofibrosis
- Author
-
Ditschkowski, Markus, Elmaagacli, Ahmet H., Trenschel, Rudolf, Steckel, Nina K., Koldehoff, Michael, and Beelen, Dietrich W.
- Published
- 2006
- Full Text
- View/download PDF
39. Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia?
- Author
-
Ringden, Olle, Labopin, Myriam, Solders, Martin, Beelen, Dietrich W., Arnold, Renate, Ehninger, Gerhard, Milpied, Noel, Niederwieser, Dietger, Hamladji, Rose-Marie, Ganser, Arnold, Socié, Gerard, Stelljes, Matthias, Volin, Liisa, Craddock, Charles, and Mohty, Mohamad
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.